http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Edwards Lifesciences (EW) sees 2022 adjusted earnings per share $2.50 - $2.65
-
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
-
Edwards Lifesciences (EW) Reports Six-month Data From Transcatheter Tricuspid Replacement Program
-
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
-
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
-
Edwards Lifesciences Reports Third Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021
-
Edwards Lifesciences Reports Second Quarter Results
-
Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR
-
Edwards Lifesciences To Host Earnings Conference Call On July 29, 2021
-
Edwards Lifesciences (EW) Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
-
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
-
Edwards Lifesciences (EW) Says Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
-
Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
-
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
-
Edwards Lifesciences (EW) board authorized additional $1 billion for share repurchases
-
Edwards Announces Updates From Annual Meeting
-
Edwards Lifesciences Reports First Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021
-
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
-
Edwards Lifesciences Reports Fourth Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021
-
Edwards Lifesciences (EW) Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
-
Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
-
Edwards Lifesciences (EW) outlines growth strategy, sees 2021 adjusted EPS of $2.00-2.20
-
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
-
Edwards Lifesciences Reports Third Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020
-
Edwards Lifesciences Reports Second Quarter Results
-
Edwards Lifesciences (EW) Announces KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries
-
Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries
-
Paul LaViolette Appointed To Edwards Lifesciences Board Of Directors
-
Abbott (ABT) Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences (EW)
-
Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott
-
Edwards Lifesciences To Host Earnings Conference Call On July 23, 2020
-
Edwards Lifesciences (EW) SAPIEN 3 Transcatheter Heart Valve Receives Approval In China
-
Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China
-
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
-
Edwards Announces Updates From Annual Meeting
-
Edwards Lifesciences Announces May 2020 Investor Conference Schedule
-
Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients
-
Edwards Lifesciences Reports First Quarter Results
-
Edwards Lifesciences To Hold Virtual Annual Meeting Of Stockholders
-
Edwards Lifesciences To Host Earnings Conference Call On April 23, 2020
-
Edwards Lifesciences (EW) Halts Enrollments in Pivotal Mitral, Tricuspid Trials In Response to Hospitals' Focus On COVID-1
-
Edwards SAPIEN 3 Valve Shows Excellent Results At 2 Years
-
Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19
-
Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference
-
Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients
-
Edwards Lifesciences Reports Fourth Quarter Results

